Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.00 | -28.22K | 0.00 | 0.00 | -286.00 |
EBITDA | -5.47M | -4.50M | -3.37M | -4.14M | -2.55M |
Net Income | -5.53M | -5.00M | -3.56M | -4.52M | -2.79M |
Balance Sheet | |||||
Total Assets | 1.96M | 4.32M | 8.04M | 11.06M | 879.25K |
Cash, Cash Equivalents and Short-Term Investments | 1.84M | 4.06M | 7.98M | 10.37M | 671.09K |
Total Debt | 0.00 | 0.00 | 344.23K | 318.43K | 1.37M |
Total Liabilities | 942.76K | 655.25K | 1.12M | 1.12M | 2.03M |
Stockholders Equity | 1.01M | 3.67M | 6.92M | 9.94M | -1.15M |
Cash Flow | |||||
Free Cash Flow | -4.22M | -3.85M | -2.00M | -2.80M | -1.35M |
Operating Cash Flow | -4.22M | -3.70M | -1.99M | -2.80M | -1.35M |
Investing Cash Flow | 2.80M | 4.78M | 1.60M | -9.91M | 0.00 |
Financing Cash Flow | 1.96M | 0.00 | 0.00 | 12.58M | 1.22M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
78 Outperform | $3.78B | 16.43 | 37.24% | ― | 22.42% | ― | |
62 Neutral | $954.10M | ― | -40.13% | ― | ― | -3.08% | |
54 Neutral | $5.05B | ― | -282.16% | ― | 72.16% | 9.65% | |
52 Neutral | $7.46B | -0.04 | -63.82% | 2.49% | 16.43% | <0.01% | |
40 Underperform | $8.26M | ― | 234.90% | ― | ― | 62.35% | |
35 Underperform | $50.08M | ― | -280.78% | ― | ― | 68.75% | |
27 Underperform | $2.90M | ― | -512.79% | ― | ― | -40.51% |
On February 21, 2025, Protagenic Therapeutics Inc. held its 2024 Annual Meeting of Stockholders, where stockholders approved a proposal to reprice certain outstanding stock options under the company’s 2006 and 2016 Equity Incentive Plans. The Board of Directors subsequently repriced these options to an exercise price of $0.2655 per share, aligning with the closing price of the company’s common stock on that date, potentially impacting the company’s financial strategy and stakeholder interests.